Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | PPARG | P37231 | 12/20 | 0.54 |
| ▸ | PPARA | Q07869 | 10/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586583 | 0.85 | PPARG (0.51) | KDM4EHRH3PPARGPPARAHPGD | |
| SCHEMBL5737604 | 0.85 | HRH3 (0.57) | KDM4EHRH3PPARGPPARAHPGD | |
| SCHEMBL6383756 | 0.84 | KDM4E (0.63) | KDM4EHRH3PPARGPPARAHPGD | |
| SCHEMBL12617863 | 0.83 | PPARG (0.69) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL7491201 | 0.82 | FFAR1 (0.53) | KDM4EPPARGPPARAHPGDPPARD | |
| SCHEMBL2979513 | 0.81 | HRH3 (0.59) | KDM4EHRH3PPARGPPARAHPGD | |
| SCHEMBL10058004 | 0.81 | HRH3 (0.62) | KDM4EHRH3PPARGPPARAHPGD | |
| SCHEMBL3761024 | 0.81 | KDM4E (0.58) | KDM4EHRH3PPARGPPARAHPGD | |
| SCHEMBL12617786 | 0.80 | PPARG (0.67) | PPARGPPARA | |
| SCHEMBL979145 | 0.80 | KDM4E (0.65) | KDM4EHRH3PPARGPPARAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| CN-1805943-A | Alpha substituted carboxylic acid as PPAR modulators | PFIZER (US) | 2006-07-19 | — | — | CN | disclosed |
| EP-1615899-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS PPAR MODULATORS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050234066-A1 | Alpha substituted carboxylic acids | AGOURON PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PFIZER INC | 2005-08-25 | — | — | US | disclosed |
| WO-2004092145-A1 | ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS | PFIZER INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234066-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | KDM4E 3007/4885HRH3 651/4885PPARG 1/4885 |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | KDM4E 3007/4885HRH3 651/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.